Zacks Investment Research · Apr 18, 2022
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
OTC · KLDO
Kaleido Biosciences, Inc.
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 6:56 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.26K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.20
- Volume
- 260
- Avg. volume
- 3.61K
Price performance
KLDO price history
1M range · 13 trading sessions · Daily adjusted prices
KLDO closed at $0.00 after 13 trading sessions, up 0.00% for the selected period.
- Last close
- $0.00
- Period change
- +0.00%
- Period low
- $0.00
- Period high
- $0.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 260 |
| Aug 18, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 605 |
| Aug 17, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 2.26K |
| Aug 13, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 605 |
| Aug 12, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 2.35K |
| Aug 11, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 400 |
| Aug 10, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 730 |
| Aug 7, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 570 |
| Aug 6, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 1.8K |
| Aug 4, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 1.81K |
| Jul 31, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 700 |
| Jul 29, 2026 | $0.00 | $0.00 | $0.00 | $0.00 | 987 |
| Jul 27, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 4.24K |
Latest KLDO news
The latest Smart Investors Daily articles mentioning KLDO.
Stock researchCompany · Overview
KLDO research
Overview
Company profile and research snapshot.
Company profile
KALEIDO BIOSCIENCES INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Sell
- Average target
- $22.44
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 4, 2022 | Chardan Capital | Neutral | — |
| Jan 31, 2022 | Chardan Capital | Buy | — |
| Nov 12, 2021 | Chardan Capital | Buy | — |
| Nov 3, 2021 | JMP Securities | Market Outperform | — |
| Oct 19, 2021 | Morgan Stanley | Underweight | — |
News briefing
No generated briefing is available yet.
PennyStocks · Apr 13, 2022
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research · Apr 1, 2022
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Zacks Investment Research · Apr 1, 2022
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
